Eupraxia Pharmaceuticals Upgrades to Nasdaq Global Select Market…

Event summary

Eupraxia Pharmaceuticals' shares began trading on the Nasdaq Global Select Market on September 8, 2026, upgrading from the Nasdaq Capital Market.
The company will maintain its listing on the Toronto Stock Exchange under the same ticker symbol (EPRX).
Eupraxia's management will participate in three investor conferences in September 2026, including Cantor Global Healthcare, H.C. Wainwright Global Investment, and Morgan Stanley Global Healthcare.
Eupraxia's Diffusphere™ technology is currently being tested in a Phase 1b/2 trial (RESOLVE) for treating EoE via localized esophageal drug delivery.

The big picture

Eupraxia's upgrade to the Nasdaq Global Select Market signals confidence in its financial stability and governance, aligning with broader trends of biotech companies seeking premium listings to enhance credibility. The company's proprietary Diffusphere™ technology positions it in a competitive space where localized drug delivery could redefine treatment paradigms in inflammatory diseases and beyond. Success will hinge on executing clinical milestones while maintaining investor momentum.

What we're watching

Market Perception: Whether the Nasdaq Global Select Market upgrade will enhance Eupraxia's visibility and attractiveness to institutional investors.
Clinical Progress: The pace at which Eupraxia advances its Diffusphere™-based pipeline, particularly the Phase 1b/2 RESOLVE trial for EoE.
Investor Engagement: How effectively Eupraxia's management communicates its long-term strategy during upcoming investor conferences.